Skills summary

Identifying and evaluating new opportunities

Led market identification and positioning for PRIME ECG®, a novel cardiovascular diagnostic device: raised $22M in B-round financing, and built Management and field team to achieve 23% CAGR across 30 prestigious institutions nationwide, ultimately achieving exit for sale to medical device subsidiary of $5B Fortune 1000 company

Expanded privately-held clinical marketing business from $6.5M to $21M with 16 multinational pharmaceutical clients in 5 years; launched successful Canadian affiliate; initiated merger discussions with Medco-owned public company to expand business and value proposition for clients

Co-chaired Merck task force in pharmacogenomics to establish presence in human genome research

Developed first Merck Worldwide Marketing initiative specific to hospital products

Coordinated strategy, developed opportunity analysis for multi-billion dollar acquisition of A. H. Robins by American Home Products

Optimizing product adoption

Developed effective strategy to support launch of PRIME ECG technology, leading to 20-40% target physician utilization on eligible patients within months of launch at major medical centers nationwide

Led or supported 10 product launches in cardiovascular, anti-infective, anti-fungal, diabetes, migraine, asthma, anemia, chemotherapy-induced emesis, HIV and oncology categories

Led re-branding/re-positioning of six year old acute CV product; created new selling skills module, launched new sales force and realigned existing sales force

Led development of Millennium customer segment/key opinion leader and channel strategies

Forging strategic relationships and partnerships

Played key role as senior business development executive in conceptualizing and negotiating five Medco disease management alliances and one joint venture with major pharmaceutical companies

Negotiated licensing of point-of-care electronic Rx software for Medco

Supported acquisition analysis and led successful integration of Cor Therapeutics and Millennium commercial businesses

Effectively managed large biotech-pharma partnerships in cardiovascular disease, inflammatory disease, and diagnosticsLed negotiations with Genentech and Schering-Plough for CV trial partnerships

Negotiated expanded license agreement between SciFluor and Harvard University to add radiochemistry technology license to existing fluorine licenses

Along with SciFluor team, initiated broad range of partnering discussions around SciFluor small molecules and completed three transactions around radiochemistry capabilities

Developing strategies to maximize growth

Worked with scientific team at SciFluor to file IP and begin preclinical development of 13 new compounds (NCEs)

Led development of second generation disposable and next-generation workstation to optimize life cycle and improve adoption of PRIME ECG technology at start-up medical device company

Established and led teams to support Merck international managed care pilot initiatives in 7 countries worldwide

Responsible for commercial  strategy on Merck ophthalmic, anti-infective, and anti-platelet Worldwide Business Strategy Teams

Developed pharmacogenomics strategy for Merck Marketing

Built Millennium Inflammation Strategic Business Team as matrix-managed functional strategic unit

Established Millennium New Product Marketing organization, and developed Millennium Marketing Foundations program to guide all commercial aspects of product development